证券代码：300642 证券简称：透景生命 公告编号：2025-040 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 上海透景生命科技股份有限公司 关于回购公司股份的进展公告 二、其他说明 公司后续将根据市场情况在本次回购股份方案规定的回购期限内择机做出 回购决策并予以实施，并将在回购期间根据相关法律、法规和规范性文件的规定 及时履行信息披露义务，敬请广大投资者注意投资风险。 特此公告。 上海透景生命科技股份有限公司 董 事 会 上海透景生命科技股份有限公司（以下简称"公司"）于 2025 年 4 月 8 日 召开第四届董事会第八次会议，审议通过了《关于以集中竞价交易方式回购公司 股份的议案》。本次回购的股份用于股权激励或员工持股计划，用于回购股份的 资金总额不低于人民币 2,000 万元（含）且不超过人民币 4,000 万元（含），回 购股份价格不超过 16.00 元/股（含），实施期限为自公司董事会审议通过本次 回购股份方案之日起 12 个月内。具体内容请详见公司分别于 2025 年 4 月 8 日、 2025 年 4 月 14 日在巨潮资讯网（www. ...

证券代码：300642 证券简称：透景生命 公告编号：2025-039 上海透景生命科技股份有限公司 关于特定股东减持公司股份的预披露公告 特定股东上海荣振投资集团有限公司保证向本公司提供的信息内容真实、 准确、完整，没有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一 致。 特别提示： 持有上海透景生命科技股份有限公司（以下简称"公司"或"透景生命"） 股份 2,364,895 股（占公司总股本注1比例 1.47%）的股东上海荣振投资集团有限 公司（以下简称"荣振投资"或"股东"）自本公告披露之日起 3 个交易日后的 3 个月内以证券交易所集中竞价交易方式或大宗交易方式减持公司股份不超过 1,150,000 股（占公司总股本 0.71%）。 公司于近日收到股东荣振投资出具的《关于计划减持公司股份的告知函》， 现将有关内容公告如下： 一、股东基本情况 | 股东名称 | 持股数量（股） | 占公司总股本的比例 | | --- | --- | --- | | 上海荣振投资集团有限公司 | 2,364,895 | 1.47% | 减持期间：自本公告披露日起 3 个交易 ...

透景生命（300642）公告，持有公司1.47%股份的股东上海荣振投资集团有限公司计划自公告披露日起 3个交易日后的3个月内，通过证券交易所集中竞价交易或大宗交易方式减持不超过115万股，占公司总 股本0.71%。 ...

证券代码：300642 证券简称：透景生命 公告编号：2025-038 上海透景生命科技股份有限公司 关于持股 5%以上股东股份解除质押及质押的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 注 2：上述比例均按照四舍五入保留两位小数计算，下同。若出现合计数与各分项数据 之和尾数不符的，均为四舍五入原因所致。 2、本次股份质押基本情况 | 股东 | 是否为控股股东 | 本次质押数 | 占其所 | 占公司 | 是否 | 是否为 | 质押起 | 质押到 | | | 质押 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 名称 | 或第一大股东及 | 量（股） | 持股份 | 总股本 | 为限 | 补充质 | 始日 | 期日 | | 质权人 | 用途 | | | 其一致行动人 | | 比例 | 比例 | 售股 | 押 | | | | 上海浦东 | | | 凌飞 | | | | | | | 2025 年 | 2028 | 年 | 发展银行 | 自身 | | ...

上海透景生命科技股份有限公司的主营业务是自主品牌的体外诊断产品的研发、生产和销售。公司的主 要产品是体外诊断试剂、体外诊断仪器、服务收入。公司积极参与各类健康主题公益活动，比如全国三 八妇女节公益活动、全国子宫颈癌和乳腺癌防治咨询公益活动等，践行社会担当，并连续多年荣获中国 癌症基金会颁发的"社会公益奖"等多项奖项，积极履行社会责任。 5月27日，透景生命今日收盘14.02元，上涨1.37%，滚动市盈率PE（当前股价与前四季度每股收益总和 的比值）达到57.87倍，总市值22.86亿元。 从行业市盈率排名来看，公司所处的医疗器械行业市盈率平均49.11倍，行业中值35.89倍，透景生命排 名第93位。 截至2025年一季报，共有5家机构持仓透景生命，其中其他5家，合计持股数2803.88万股，持股市值4.03 亿元。 最新一期业绩显示，2025年一季报，公司实现营业收入7489.31万元，同比-19.53%；净利润47.17万元， 同比110.51%，销售毛利率63.66%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)93透景生命57.8766.181.5222.86亿行业平均 49.1147.3 ...

上海透景生命科技股份有限公司的主营业务是自主品牌的体外诊断产品的研发、生产和销售。公司的主 要产品是体外诊断试剂、体外诊断仪器、服务收入。公司积极参与各类健康主题公益活动，比如全国三 八妇女节公益活动、全国子宫颈癌和乳腺癌防治咨询公益活动等，践行社会担当，并连续多年荣获中国 癌症基金会颁发的"社会公益奖"等多项奖项，积极履行社会责任。 最新一期业绩显示，2025年一季报，公司实现营业收入7489.31万元，同比-19.53%；净利润47.17万元， 同比110.51%，销售毛利率63.66%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)93透景生命56.9665.141.4922.50亿行业平均 48.7146.924.57105.44亿行业中值35.3737.132.4047.42亿1天益医疗-1727.26-2958.601.8422.01亿2澳华内 镜-604.66303.274.8463.72亿3诺唯赞-406.65-480.962.2387.02亿4爱朋医疗-349.63265.624.2128.69亿5博晖 创新-321.82510.673.4347.22亿6硕世生物-133.72-1 ...

资金流向方面，5月20日，透景生命主力资金净流出337.53万元，近5日总体呈流入状态，5日共流入 166.88万元。 上海透景生命科技股份有限公司的主营业务是自主品牌的体外诊断产品的研发、生产和销售。公司的主 要产品是体外诊断试剂、体外诊断仪器、服务收入。公司积极参与各类健康主题公益活动，比如全国三 八妇女节公益活动、全国子宫颈癌和乳腺癌防治咨询公益活动等，践行社会担当，并连续多年荣获中国 癌症基金会颁发的"社会公益奖"等多项奖项，积极履行社会责任。 5月20日，透景生命今日收盘14.12元，上涨1.58%，滚动市盈率PE（当前股价与前四季度每股收益总和 的比值）达到58.28倍，创30天以来新低，总市值23.02亿元。 最新一期业绩显示，2025年一季报，公司实现营业收入7489.31万元，同比-19.53%；净利润47.17万元， 同比110.51%，销售毛利率63.66%。 从行业市盈率排名来看，公司所处的医疗器械行业市盈率平均49.51倍，行业中值36.17倍，透景生命排 名第92位。 序号股票简称PE(TTM)PE(静)市净率总市值(元)92透景生命58.2866.651.5323.02亿行业平均 ...

Core Viewpoint - The company faced significant revenue decline in 2024 due to market environment changes and centralized procurement policies, impacting its financial performance and product sales [1][2]. Financial Performance - In 2024, the company reported total revenue of 437 million yuan, a decrease of 19.53% year-on-year, with a net profit attributable to shareholders of 35 million yuan, down 61.37% [1]. - For Q4 2024, revenue was 116 million yuan, a decline of 18.19%, and net profit attributable to shareholders was 10 million yuan, down 78.19% [1]. - In Q1 2025, revenue was 75 million yuan, a decrease of 19.53%, but the company achieved a net profit of 470,000 yuan, marking a return to profitability [1]. Market Impact - The implementation of centralized procurement led to a significant drop in revenue from HPV products, which saw a year-on-year decline of 31.38% [2]. - Revenue from third-party testing clients decreased by 51.17% due to price sensitivity, while direct sales to third-party and screening clients fell by 31.76% [2]. - Revenue from hospital clients, which are less affected by centralized procurement, declined by 13.70%, indicating a more stable revenue stream compared to other client segments [2]. R&D and Strategic Initiatives - The company increased its R&D expenditure to 15.05% of revenue, focusing on over 70 projects across various technology platforms [3]. - Clinical research for cervical cancer screening and expansion of methylation detection sample types were completed in 2024 [3]. - The company entered the fungal detection field through acquisitions and invested in dry eye disease and AI sectors, enhancing its innovation pipeline [3]. Future Outlook - The company anticipates continued pressure in Q1 2025 due to industry policies and reduced HPV usage among price-sensitive clients [3]. - Projected net profits for 2025-2027 are estimated at 40 million, 50 million, and 60 million yuan, reflecting year-on-year growth rates of 5.7%, 27.2%, and 32.9% respectively [3]. - The company's reasonable market value is estimated at 2.6 billion yuan, with a target price of 16 yuan per share, maintaining a "recommended" rating [3].

Investment Rating - The report maintains a "Recommendation" rating for the company, with a target price of 16 yuan [2][8]. Core Views - The company's performance is under pressure, with a significant decline in revenue and net profit for 2024. The total revenue for 2024 is reported at 437 million yuan, down 19.53% year-on-year, and the net profit attributable to the parent company is 34 million yuan, down 61.4% [2][4]. - The company is focusing on self-research and acquisitions to enrich its product pipeline, with a research and development expense ratio of 15.05% in 2024. The company has completed clinical research for cervical cancer screening and expanded its methylation detection sample types [2][8]. - The first quarter of 2025 continues to show pressure, with revenue of 75 million yuan, down 19.53% year-on-year, but the company managed to turn a profit with a net profit of 470,000 yuan [2][4]. Financial Summary - For 2024, the total revenue is 437 million yuan, with a year-on-year growth rate of -19.5%. The net profit attributable to the parent company is 34 million yuan, with a year-on-year growth rate of -61.4% [4]. - The projected financials for 2025 to 2027 show a gradual recovery, with net profits expected to grow to 36 million yuan in 2025, 46 million yuan in 2026, and 62 million yuan in 2027, reflecting growth rates of 5.7%, 27.2%, and 32.9% respectively [4][8]. - The company's earnings per share (EPS) is projected to be 0.21 yuan in 2024, increasing to 0.22 yuan in 2025, 0.28 yuan in 2026, and 0.38 yuan in 2027 [4][8].

Group 1: Company Overview - The company is Shanghai TuoJing Life Science Technology Co., Ltd., which held an annual performance briefing on May 15, 2025 [2][4]. - Key attendees included the Chairman and General Manager Mr. Yao Jian'er, Vice General Manager and Secretary of the Board Mr. Wang Xiaoqing, Financial Officer Mr. Li Songtao, and Independent Director Mr. Zhao Jiaxiang [2][4]. Group 2: Financial Performance and Share Buyback - In 2024, the company executed a share buyback plan with a total expenditure of RMB 25,979,178.00 (excluding transaction fees) [5]. - A new share buyback plan was approved on April 8, 2025, with a budget of RMB 20 million to 40 million, aimed at supporting stockholder rights and future employee stock ownership plans [5]. Group 3: Cost Reduction and Efficiency Measures - The company has implemented several cost reduction and efficiency measures in response to industry-wide procurement initiatives, including optimizing production processes and relocating low-margin products to lower-cost facilities [5]. - These measures aim to stabilize the overall gross margin and reduce depreciation costs associated with equipment installation [5]. Group 4: Research and Development Achievements - The company has prioritized R&D, participating in national key projects and being recognized as a high-tech enterprise and a "little giant" in specialized fields [6]. - As of the end of 2024, the company has filed 57 invention patents, with 27 granted, and has launched several pioneering products in clinical diagnostics [6]. - Future R&D investments will focus on areas such as oncology, autoimmune diseases, thrombosis, infectious diseases, and cytokines [6].